Denali Therapeutics is a California-based biopharmaceutical company that develops treatments for neurological and rare diseases. According to filings, it lobbies on health-related issues, especially efforts to reauthorize the Rare Pediatric Disease Priority Review Voucher program and other policies that affect rare disease drug development. It has reported hiring the firm Manatt, Phelps, and Phillips and spent about $413,000 across seven filings.
Show the dominant industry call, how mixed the client looks, and the allocation across the top labeled sectors.
Annual totals based on disclosed filing amounts.
Issue rankings are based on disclosed activity mentions, with filing amounts apportioned evenly across issues within the same filing.
The lobbying registrants handling this client, ranked by disclosed filing amounts.
Lobbyists are ranked by appearances and an equal share of each filing's reported amount.
HEIDE BAJNRAUH
The latest disclosures for this client.
MANATT, PHELPS, AND PHILLIPS
Q2YMANATT, PHELPS, AND PHILLIPS
Q1The entities named in disclosed activities are the clearest available signal for where the client is aiming attention.
This client's filings do not yet disclose named government entities.
MANATT, PHELPS, AND PHILLIPS
mrs KENDALL BYRUM HUSSEY
MANATT, PHELPS, AND PHILLIPS
RACHEL SHER
MANATT, PHELPS, AND PHILLIPS
MANATT, PHELPS, AND PHILLIPS
Q4MANATT, PHELPS, AND PHILLIPS
Q3MANATT, PHELPS, AND PHILLIPS
Q2MANATT, PHELPS, AND PHILLIPS
1AMANATT, PHELPS, AND PHILLIPS
Q1MANATT, PHELPS, AND PHILLIPS
RR